



# FINANCIAL TEAR SHEET

## Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

## Stock Performance

### APRI (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$1.73</b>
Change (%)	0.00 (0.00%)
Volume	355
52 Week High	\$4.07
52 Week Low	\$0.86
Market Cap	\$22,115,907
Rolling EPS	-0.83
PE Ratio	0
Shares Outstanding	12,783,761

Data as of 09/25/17 4:00 p.m. ET



## Recent Headlines

09/11/17

[Apricus Biosciences Announces \\$3.7 Million Private Placement Priced At-The-Market](#)

09/05/17

[Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference](#)

08/31/17

[Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
09/25/17	S-3
09/25/17	RW
09/20/17	SC 13G
09/11/17	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

---

© Apricus Biosciences, Inc.